Paluszczak Jaroslaw, Baer-Dubowska Wanda
Department of Pharmaceutical Biochemistry, Poznań University of Medical Sciences, Grunwaldzka 6, 60-780 Poznań, Poland.
J Appl Genet. 2006;47(4):365-75. doi: 10.1007/BF03194647.
In recent years it has become apparent that epigenetic events are potentially equally responsible for cancer initiation and progression as genetic abnormalities. DNA methylation is the main epigenetic modification in humans. Two DNA methylation lesions coexist in human neoplasms: hypermethylation of promoter regions of specific genes within a context of genomic hypomethylation. Aberrant methylation is found at early stages of carcinogenesis and distinct types of cancer exhibit specific patterns of methylation changes. Tumor specific DNA is readily obtainable from different clinical samples and methylation status analysis often permits sensitive disease detection. Methylation markers may also serve for prognostic and predictive purposes as they often reflect the metastatic potential and sensitivity to therapy. As current findings show a great potential of recently characterised methylation markers, more studies in the field are needed in the future. Large clinical studies of newly developed markers are especially needed. The review describes the diagnostic potential of DNA methylation markers.
近年来,表观遗传事件在癌症的发生和发展中所起的作用已变得明显,其重要性可能与基因异常不相上下。DNA甲基化是人类主要的表观遗传修饰。两种DNA甲基化损伤共存于人类肿瘤中:在基因组低甲基化的背景下,特定基因启动子区域的高甲基化。异常甲基化在癌变的早期阶段即可发现,不同类型的癌症表现出特定的甲基化变化模式。肿瘤特异性DNA很容易从不同的临床样本中获取,甲基化状态分析通常能实现疾病的灵敏检测。甲基化标志物还可用于预后和预测,因为它们往往反映转移潜能和对治疗的敏感性。鉴于目前的研究结果显示了近期鉴定出的甲基化标志物具有巨大潜力,未来该领域需要开展更多研究。尤其需要针对新开发标志物开展大型临床研究。本文综述阐述了DNA甲基化标志物的诊断潜力。